Fiona Maclean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fiona Maclean has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Ana Cristina Vargas
Department of Anatomical Pathology, Sonic Healthcare - Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia
5 shared publications - Andres Martin Acosta
Department of Pathology, Indiana University, Indianapolis, USA
5 shared publications - Sean R. Williamson
Department of Pathology, Cleveland Clinic, Cleveland, OH
5 shared publications - Adeboye O. Osunkoya
Departments of Pathology and Urology, Emory University School of Medicine, Atlanta, GA
4 shared publications - Ankur R. Sangoi
Department of Pathology, Stanford Medical Center, Stanford, CA
4 shared publications - Chia‐Sui Kao
Robert J. Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland Ohio USA
4 shared publications
Latest Publications
- Open Access
- 18 April 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-6
FGFR1 mutations identified in FOXL2-wild type ovarian adult granulosa cell tumors are not present in testicular counterparts: Re-analysis of a multi-institutional series
Testicular adult granulosa cell tumors (AGCTs) are rare and show several clinical, pathological, and molecular differences with their ovarian counterparts. FOXL2 p.Cys134Trp, the ubiquitous molecular driver of ovarian AGCTs, is infrequent (~ 7%) in testicular AGCTs. Recently, FGFR1 hotspot mutations were reported as a potentially “alternative molecular driver” in FOXL2 -wild type (WT) ovarian AGCTs. A systematic assessment of FGFR1 status has not been performed in testicular AGCTs. Recently, our group analyzed a series of twenty testicular AGCTs using two NGS panels that lacked coverage of FGFR1 . Among twelve cases analyzed successfully, none harbored pathogenic FOXL2 variants. In this study, we reassessed the tumors from our prior series with an NGS panel that covers FGFR1 . Among the 14 tumors (70%) that were sequenced successfully, none harbored pathogenic FGFR1 variants. Considering the AGCTs assessed in this study and those previously reported in the literature, none of the 24 tumors analyzed to date have shown pathogenic FGFR1 variants. The present study reinforces the concept that testicular sex cord-stromal tumors classified as AGCTs are different from ovarian counterparts.
- 18 April 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-6
Open AccessFGFR1 mutations identified in FOXL2-wild type ovarian adult granulosa cell tumors are not present in testicular counterparts: Re-analysis of a multi-institutional series
Testicular adult granulosa cell tumors (AGCTs) are rare and show several clinical, pathological, and molecular differences with their ovarian counterparts. FOXL2 p.Cys134Trp, the ubiquitous molecular driver of ovarian AGCTs, is infrequent (~ 7%) in testicular AGCTs. Recently, FGFR1 hotspot mutations were reported as a potentially “alternative molecular driver” in FOXL2 -wild type (WT) ovarian AGCTs. A systematic assessment of FGFR1 status has not been performed in testicular AGCTs. Recently, our group analyzed a series of twenty testicular AGCTs using two NGS panels that lacked coverage of FGFR1 . Among twelve cases analyzed successfully, none harbored pathogenic FOXL2 variants. In this study, we reassessed the tumors from our prior series with an NGS panel that covers FGFR1 . Among the 14 tumors (70%) that were sequenced successfully, none harbored pathogenic FGFR1 variants. Considering the AGCTs assessed in this study and those previously reported in the literature, none of the 24 tumors analyzed to date have shown pathogenic FGFR1 variants. The present study reinforces the concept that testicular sex cord-stromal tumors classified as AGCTs are different from ovarian counterparts.
- Open Access
- 16 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 303-311
Immunophenotypic assessment of pure embryonal carcinoma and yolk sac tumour suggests that reprogramming to non‐seminoma occurs outside the spermatogonial niche
Aims: Germ cell neoplasia in situ (GCNIS) is the precursor of GCNIS‐derived testicular germ cell tumours, including seminomas and non‐seminomas. Most non‐seminomas show mixed histology, often including components of seminoma. A small subset presents as pure non‐seminomatous germ cell tumors. In these neoplasms, the absence of invasive seminoma. raises the possibility that reprogramming to non‐seminoma may occur at an early in‐situ stage (i.e., within the spermatogonial niche). This study examined GCNIS associated with pure embryonal carcinoma (EC) and postpubertal‐type yolk sac tumour (YST) using immunohistochemistry for transcription factors characteristic of GCNIS/seminoma, EC, and YST phenotypes to determine if reprogramming to non‐seminoma occurs within the spermatogonial niche. Methods: GCNIS associated with pure testicular YST and EC was assessed using OCT4, FOXA2 (only YST), CD30 (only EC), SOX2 (only EC), SOX17, and NANOG immunohistochemistry. Adjacent foci of intratubular and invasive tumour were also evaluated, if present. Results: Sixty‐seven pure non‐seminomas (63 EC, 4 YST) were evaluated. In all cases, GCNIS expressed OCT4, SOX17, and NANOG. GCNIS associated with EC was consistently negative for CD30 and SOX2, and GCNIS associated with YST was consistently negative for FOXA2. Adjacent invasive EC (62/67 cases) and intratubular EC (19/67) showed the classic EC immunophenotype: OCT4+/NANOG+/SOX17–/SOX2+/CD30+. Similarly, invasive YST adjacent to GCNIS was OCT4–/NANOG–/SOX17+/FOXA2+. Conclusions: Assessment of transcription factors involved in the induction and maintenance of EC and YST phenotypes suggests that, in pure non‐seminomas, reprogramming occurs outside the spermatogonial niche.
- 16 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 303-311
Open AccessImmunophenotypic assessment of pure embryonal carcinoma and yolk sac tumour suggests that reprogramming to non‐seminoma occurs outside the spermatogonial niche
Aims: Germ cell neoplasia in situ (GCNIS) is the precursor of GCNIS‐derived testicular germ cell tumours, including seminomas and non‐seminomas. Most non‐seminomas show mixed histology, often including components of seminoma. A small subset presents as pure non‐seminomatous germ cell tumors. In these neoplasms, the absence of invasive seminoma. raises the possibility that reprogramming to non‐seminoma may occur at an early in‐situ stage (i.e., within the spermatogonial niche). This study examined GCNIS associated with pure embryonal carcinoma (EC) and postpubertal‐type yolk sac tumour (YST) using immunohistochemistry for transcription factors characteristic of GCNIS/seminoma, EC, and YST phenotypes to determine if reprogramming to non‐seminoma occurs within the spermatogonial niche. Methods: GCNIS associated with pure testicular YST and EC was assessed using OCT4, FOXA2 (only YST), CD30 (only EC), SOX2 (only EC), SOX17, and NANOG immunohistochemistry. Adjacent foci of intratubular and invasive tumour were also evaluated, if present. Results: Sixty‐seven pure non‐seminomas (63 EC, 4 YST) were evaluated. In all cases, GCNIS expressed OCT4, SOX17, and NANOG. GCNIS associated with EC was consistently negative for CD30 and SOX2, and GCNIS associated with YST was consistently negative for FOXA2. Adjacent invasive EC (62/67 cases) and intratubular EC (19/67) showed the classic EC immunophenotype: OCT4+/NANOG+/SOX17–/SOX2+/CD30+. Similarly, invasive YST adjacent to GCNIS was OCT4–/NANOG–/SOX17+/FOXA2+. Conclusions: Assessment of transcription factors involved in the induction and maintenance of EC and YST phenotypes suggests that, in pure non‐seminomas, reprogramming occurs outside the spermatogonial niche.
- Open Access
- 20 November 2025
- Published by Wiley in Histopathology
- Vol. 88 (4) , 831-842
Adult granulosa cell tumours of the testis analogous to ovarian counterparts are exceptionally rare: analysis of a multicentric series and review of the literature
Aims: Testicular adult granulosa cell tumours (AGCTs) are rare and show several clinical–pathological differences with their ovarian counterparts. In a limited number of prior studies, FOXL2 p.Cys134Trp, the hallmark molecular alteration of ovarian AGCT, appeared to be infrequent in testicular AGCTs. However, the number of cases analysed to date is relatively small. Methods and results: Twenty testicular AGCTs were analysed de novo using two different next‐generation sequencing ( NGS ) panels that cover sex cord‐stromal tumour ( SCST )–relevant genes, including FOXL2 , CTNNB1 , FH and DICER1 . Among 12 tumours (12/20; 60%) that were sequenced successfully, none harboured FOXL2 mutations. Eight tumours (8/12, 66.7%) showed a wild‐type ( WT ) status for all genes assessed with the panels. Three tumours harboured pathogenic or likely pathogenic CTNNB1 alterations. One of these exhibited predominant spindle cell morphology, while the other two showed focal tubular architecture. Immunohistochemistry performed in one of these tumours with available material showed β‐catenin expression in ~70% of tumor cell nuclei. The remaining AGCTs showed variants of uncertain significance (likely benign) in KIT and MED12 . Considering the tumors asseseed in this study and those previously reported in the literature, only 2 of 29 neoplasms classified as testicular AGCTs have shown a FOXL2 p. Cys134Trp mutation to date. Conclusions: The present study confirms that SCSTs classified as AGCTs differ from their ovarian counterparts in that they largely lack FOXL2 mutations.
- 20 November 2025
- Published by Wiley in Histopathology
- Vol. 88 (4) , 831-842
Open AccessAdult granulosa cell tumours of the testis analogous to ovarian counterparts are exceptionally rare: analysis of a multicentric series and review of the literature
Aims: Testicular adult granulosa cell tumours (AGCTs) are rare and show several clinical–pathological differences with their ovarian counterparts. In a limited number of prior studies, FOXL2 p.Cys134Trp, the hallmark molecular alteration of ovarian AGCT, appeared to be infrequent in testicular AGCTs. However, the number of cases analysed to date is relatively small. Methods and results: Twenty testicular AGCTs were analysed de novo using two different next‐generation sequencing ( NGS ) panels that cover sex cord‐stromal tumour ( SCST )–relevant genes, including FOXL2 , CTNNB1 , FH and DICER1 . Among 12 tumours (12/20; 60%) that were sequenced successfully, none harboured FOXL2 mutations. Eight tumours (8/12, 66.7%) showed a wild‐type ( WT ) status for all genes assessed with the panels. Three tumours harboured pathogenic or likely pathogenic CTNNB1 alterations. One of these exhibited predominant spindle cell morphology, while the other two showed focal tubular architecture. Immunohistochemistry performed in one of these tumours with available material showed β‐catenin expression in ~70% of tumor cell nuclei. The remaining AGCTs showed variants of uncertain significance (likely benign) in KIT and MED12 . Considering the tumors asseseed in this study and those previously reported in the literature, only 2 of 29 neoplasms classified as testicular AGCTs have shown a FOXL2 p. Cys134Trp mutation to date. Conclusions: The present study confirms that SCSTs classified as AGCTs differ from their ovarian counterparts in that they largely lack FOXL2 mutations.
- 21 October 2025
- Published by Wiley in Histopathology
- Vol. 88 (1) , 317-337
Pathologists' nightmare or challenge accepted? Soft tissue tumours of the genitourinary tract
Soft tissue tumours of the genitourinary tract are both rare and encompass a diverse range of mesenchymal neoplasms with varied histogenesis and clinical behaviour. This review provides an up‐to‐date overview of these tumours, incorporating recent updates in classification, grading and molecular diagnostics.
- 21 October 2025
- Published by Wiley in Histopathology
- Vol. 88 (1) , 317-337
Pathologists' nightmare or challenge accepted? Soft tissue tumours of the genitourinary tract
Soft tissue tumours of the genitourinary tract are both rare and encompass a diverse range of mesenchymal neoplasms with varied histogenesis and clinical behaviour. This review provides an up‐to‐date overview of these tumours, incorporating recent updates in classification, grading and molecular diagnostics.
- Open Access
- 25 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (3) , 723-724
Correction to: Succinate dehydrogenase defcient renal cell carcinoma frequently expresses GATA3 and L1CAM
- 25 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (3) , 723-724
Open AccessCorrection to: Succinate dehydrogenase defcient renal cell carcinoma frequently expresses GATA3 and L1CAM
- 16 July 2025
- Published by Wiley in Histopathology
- Vol. 87 (5) , 768-772
Loss of expression of STK11/LKB1 in intratubular large cell hyalinizing Sertoli cell neoplasm
Aims: Intratubular large cell hyalinizing Sertoli cell neoplasia (ILCHSCN) is a rare testicular sex cord stromal tumour that occurs in paediatric patients in the context of Peutz‐Jeghers syndrome, a condition caused by germline STK11 alterations. The diagnosis of ILCHSCN and its distinction from large cell calcifying Sertoli cell tumour (LCCSCT), a neoplasm associated with loss of function PRKAR1A mutations, can be challenging. We therefore aimed to assess the immunohistochemical expression of STK11 in a cohort of ILCHSCN and LCCSCT to investigate its diagnostic utility.Methods and results: Immunohistochemistry (IHC) for STK11 was assessed in 7 ILCHSCN and 9 LCCSCT. Six ILCHSCN were also stained for PRKAR1A, a biomarker known to be lost in LCCSCT. The majority of ILCHSCN (4/7; 57%), including one case with invasion, showed complete loss of expression of STK11. All LCCSCT (9/9) showed retained STK11 expression. All ILCHSCN assessed with PRKAR1A (6/6) showed retained expression.Conclusions: The majority of ILCHSCN demonstrate loss of expression of STK11, while LCCSCT shows retained expression. Our findings support that STK11 IHC is highly specific and moderately sensitive in distinguishing between these two tumours. The combination of STK11 and PRKAR1A IHC has even greater utility for distinguishing ILCHSCN and LCCSCT.
- 16 July 2025
- Published by Wiley in Histopathology
- Vol. 87 (5) , 768-772
Loss of expression of STK11/LKB1 in intratubular large cell hyalinizing Sertoli cell neoplasm
Aims: Intratubular large cell hyalinizing Sertoli cell neoplasia (ILCHSCN) is a rare testicular sex cord stromal tumour that occurs in paediatric patients in the context of Peutz‐Jeghers syndrome, a condition caused by germline STK11 alterations. The diagnosis of ILCHSCN and its distinction from large cell calcifying Sertoli cell tumour (LCCSCT), a neoplasm associated with loss of function PRKAR1A mutations, can be challenging. We therefore aimed to assess the immunohistochemical expression of STK11 in a cohort of ILCHSCN and LCCSCT to investigate its diagnostic utility.Methods and results: Immunohistochemistry (IHC) for STK11 was assessed in 7 ILCHSCN and 9 LCCSCT. Six ILCHSCN were also stained for PRKAR1A, a biomarker known to be lost in LCCSCT. The majority of ILCHSCN (4/7; 57%), including one case with invasion, showed complete loss of expression of STK11. All LCCSCT (9/9) showed retained STK11 expression. All ILCHSCN assessed with PRKAR1A (6/6) showed retained expression.Conclusions: The majority of ILCHSCN demonstrate loss of expression of STK11, while LCCSCT shows retained expression. Our findings support that STK11 IHC is highly specific and moderately sensitive in distinguishing between these two tumours. The combination of STK11 and PRKAR1A IHC has even greater utility for distinguishing ILCHSCN and LCCSCT.
- Open Access
- 13 May 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 206-222
Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists
Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.
- 13 May 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 206-222
Open AccessCurrent practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists
Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.